U.S. Representative

Sheila Cherfilus-Mccormick 2025-2026 Regular Session - Authored & Sponsored Legislation (Page 13)

Legislative Session

Co-Sponsor of Legislation

US

US Federal 2025-2026 Regular Session

US Federal House Bill HB15

Introduced
1/3/25  
Introduced
4/29/25  
Refer
1/3/25  
Equality Act
US

US Federal 2025-2026 Regular Session

US Federal House Bill HB3868

Introduced
6/10/25  
Enhanced Background Checks Act of 2025
US

US Federal 2025-2026 Regular Session

US Federal House Bill HB3930

Introduced
6/11/25  
Roadless Area Conservation Act of 2025
US

US Federal 2025-2026 Regular Session

US Federal House Bill HR410

Introduced
5/14/25  
Expressing the sense of the House of Representatives that President Trump must comply with the Foreign Emoluments Clause, by submitting all plans for his jumbo jet gift from Qatar immediately to Congress.
US

US Federal 2025-2026 Regular Session

US Federal House Bill HB3374

Introduced
5/13/25  
Pink Tax Repeal Act
US

US Federal 2025-2026 Regular Session

US Federal House Bill HB3447

Introduced
5/15/25  
Refer
5/15/25  
Chip Security Act
US

US Federal 2025-2026 Regular Session

US Federal House Bill HB4406

Introduced
7/15/25  
State-Based Universal Health Care Act of 2025
US

US Federal 2025-2026 Regular Session

US Federal House Bill HB4443

Introduced
7/16/25  
Asunción Valdivia Heat Illness, Injury, and Fatality Prevention Act of 2025
US

US Federal 2025-2026 Regular Session

US Federal House Bill HB2548

Introduced
4/1/25  
Sanctioning Russia Act of 2025
US

US Federal 2025-2026 Regular Session

US Federal House Bill HB2550

Introduced
4/1/25  
Refer
4/1/25  
Protect America's Workforce Act
US

US Federal 2025-2026 Regular Session

US Federal House Bill HB2531

Introduced
4/1/25  
Workplace Violence Prevention for Health Care and Social Service Workers Act
US

US Federal 2025-2026 Regular Session

US Federal House Bill HB2554

Introduced
4/1/25  
Lower Drug Costs for Families Act This bill applies certain Medicare prescription drug rebate requirements to prescription drugs that are available under private health insurance. Current law requires drug manufacturers to issue rebates to the Centers for Medicare & Medicaid Services for brand-name drugs without generic equivalents under Medicare that (1) cost $100 or more per year per individual, and (2) for which prices increase faster than inflation. Manufacturers that fail to comply are subject to civil penalties. The bill applies these requirements to prescription drugs that are available in the commercial market under private health insurance. It also indexes rebate calculations to drug prices in 2016 (as opposed to 2021).
US

US Federal 2025-2026 Regular Session

US Federal House Bill HB2529

Introduced
4/1/25  
Convenient Contraception Act
US

US Federal 2025-2026 Regular Session

US Federal House Bill HB2559

Introduced
4/1/25  
Taiwan Allies Fund Act
US

US Federal 2025-2026 Regular Session

US Federal House Bill HB2576

Introduced
4/1/25  
Refer
4/1/25  
Servicemembers and Veterans Empowerment and Support Act of 2025